Adoptive cellular immunotherapy with CD19-specific T cells

Klinische Padiatrie

Volumn 217, Issue 6, 2005, Pages 351-356

  Rössig, Claudia ^a   Pscherer, S ^a   Landmeier, S ^a   Altvater, B ^a   Jurgens H ^a   Vormoor, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

ALL; CD19; Immunotherapy; T cells

Indexed keywords

CD19 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CELL PROLIFERATION; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; CHIMERA; CROSS REACTION; CYTOTOXICITY; DNA MODIFICATION; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD19; CELL LINE, TRANSFORMED; CHILD; CLONING, MOLECULAR; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; RETREATMENT; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 28544443586     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872521     Document Type: Article

References (22)

1. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Vanrhee F, Mittermueller J, Dewitte T, Holler E, Ansari H. Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients. Blood 1995; 86: 2041-2050
2. Borgmann A, Stackelberg Avon, Hartmann R, Ebell W, Klingebiel T, Peters C, Henze G. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-3839
3. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, Stackelberg Avon, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705
4. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients. Blood 1990; 76: 2462-2465
5. Cardoso AA, Veiga JP, Ghia P, Afonso HM, Haining WN, Sallan SE, Nadler LM. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood 1999; 94: 3531-3540
6. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-724
7. Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealey B, Dibirdik I, Myers DE, Tuel-Ahlgren L, Bolen JB. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem 1993; 268: 21172-21184
8. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18: 393-422
9. Rickert RC, Rajewsky K, Roes J. Impairment of T-Cell-Dependent B-Cell Responses and B-1 Cell-Development in Cd19-Deficient Mice. Nature 1995;376:352-355
10. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19- associated tyrosine kinases. Science 1995; 267: 886-891
11. Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ, Pfeiffer M, Handgretinger R, Niethammer D, Fey GH. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004; 103: 3982-3985
12. Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, Zola H, Hohmann AW. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997; 34: 1157-1165
13. Rossig C, Pscherer S, Baer A, Altvater B, Pule M, Rooney CM, Brenner MK, Juergens H, Vormoor J. Target antigen expression on a professional antigen-presenting cell induces superior proliferative anti-tumor Tcell responses via chimeric T cell receptors. J Immunother 2005; in print: -
14. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737
15. Henze G, Borgmann A, Stackelberg A von, Baumgarten E, Uchanska-Ziegler B, Ziegler A, Wittig B. Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class 1 antigen combined with interleukin-2 treatment. Journal of Molecular Medicine Jmm 1998; 76: 215-221
16. Rousseau R, Biagi E, Yvon E, Mei ZY, Inman S, Rill D, Heslop H, Popat U, Gee A, Krance R, Carrum G, Alcoser P, Rodgers S, Kuehnle I, Margolin J, Brenner M. Treatment of high-risk acute leukemia with an autologous vaccine expressing transgenic IL-2 and CD40L. Blood 2002; 100: 867A-868A
17. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey Jr RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-474
18. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76
19. Heemskerk MHM, Hoogeboom M, Hagedoorn R, Willemze R, Falkenburg JHF. Redirection of CMV-specific T-cells towards anti-leukaemic reactivity using T-cell receptor gene transfer. Bone Marrow Transplant 2004; 33: S21
20. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nature Biotechnology 2002; 20: 1221-1227
21. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002; 99: 2009-2016
22. Kimby E. Tolerability and safety of rituximab (MabThera(®)). Cancer Treatment Reviews 2005; [Epub ahead of print]